PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9710629-0	1998	Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide.	Ceramides	100-108	insulin	Homo sapiens	14-21	
9710629-0	1998	Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide.	Ceramides	100-108	solute carrier family 2 member 4	Homo sapiens	53-58	
9710629-0	1998	Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide.	Ceramides	100-108	AKT serine/threonine kinase 1	Homo sapiens	77-80	
9710629-2	1998	Recently published reports indicate that ceramide levels are elevated in insulin-responsive tissues of diabetic animals and that agents which trigger ceramide production inhibit insulin signaling.	Ceramides	41-49	insulin	Homo sapiens	73-80	
9710629-2	1998	Recently published reports indicate that ceramide levels are elevated in insulin-responsive tissues of diabetic animals and that agents which trigger ceramide production inhibit insulin signaling.	Ceramides	41-49	insulin	Homo sapiens	178-185	
9710629-2	1998	Recently published reports indicate that ceramide levels are elevated in insulin-responsive tissues of diabetic animals and that agents which trigger ceramide production inhibit insulin signaling.	Ceramides	150-158	insulin	Homo sapiens	178-185	
9710629-3	1998	In the present series of studies, the short-chain ceramide analog C2-ceramide inhibited insulin-stimulated glucose transport by approximately 50% in 3T3-L1 adipocytes, with similar reductions in hormone-stimulated translocation of the insulin-responsive glucose transporter (GLUT4) and insulin-responsive aminopeptidase.	Ceramides	50-58	insulin	Homo sapiens	88-95	
9710629-3	1998	In the present series of studies, the short-chain ceramide analog C2-ceramide inhibited insulin-stimulated glucose transport by approximately 50% in 3T3-L1 adipocytes, with similar reductions in hormone-stimulated translocation of the insulin-responsive glucose transporter (GLUT4) and insulin-responsive aminopeptidase.	N-acetylsphingosine	66-77	insulin	Homo sapiens	88-95	
9710629-3	1998	In the present series of studies, the short-chain ceramide analog C2-ceramide inhibited insulin-stimulated glucose transport by approximately 50% in 3T3-L1 adipocytes, with similar reductions in hormone-stimulated translocation of the insulin-responsive glucose transporter (GLUT4) and insulin-responsive aminopeptidase.	N-acetylsphingosine	66-77	insulin	Homo sapiens	235-242	
9710629-3	1998	In the present series of studies, the short-chain ceramide analog C2-ceramide inhibited insulin-stimulated glucose transport by approximately 50% in 3T3-L1 adipocytes, with similar reductions in hormone-stimulated translocation of the insulin-responsive glucose transporter (GLUT4) and insulin-responsive aminopeptidase.	N-acetylsphingosine	66-77	solute carrier family 2 member 4	Homo sapiens	275-280	
9710629-3	1998	In the present series of studies, the short-chain ceramide analog C2-ceramide inhibited insulin-stimulated glucose transport by approximately 50% in 3T3-L1 adipocytes, with similar reductions in hormone-stimulated translocation of the insulin-responsive glucose transporter (GLUT4) and insulin-responsive aminopeptidase.	N-acetylsphingosine	66-77	leucyl and cystinyl aminopeptidase	Homo sapiens	286-319	
9710629-3	1998	In the present series of studies, the short-chain ceramide analog C2-ceramide inhibited insulin-stimulated glucose transport by approximately 50% in 3T3-L1 adipocytes, with similar reductions in hormone-stimulated translocation of the insulin-responsive glucose transporter (GLUT4) and insulin-responsive aminopeptidase.	Glucose	107-114	insulin	Homo sapiens	88-95	
9710629-4	1998	C2-ceramide also inhibited phosphorylation and activation of Akt, a molecule proposed to mediate multiple insulin-stimulated metabolic events.	N-acetylsphingosine	0-11	AKT serine/threonine kinase 1	Homo sapiens	61-64	
9710629-4	1998	C2-ceramide also inhibited phosphorylation and activation of Akt, a molecule proposed to mediate multiple insulin-stimulated metabolic events.	N-acetylsphingosine	0-11	insulin	Homo sapiens	106-113	
9710629-6	1998	Moreover, C2-ceramide also inhibited stimulation of Akt by platelet-derived growth factor, an event that is IRS-1 independent.	N-acetylsphingosine	10-21	AKT serine/threonine kinase 1	Homo sapiens	52-55	
9710629-6	1998	Moreover, C2-ceramide also inhibited stimulation of Akt by platelet-derived growth factor, an event that is IRS-1 independent.	N-acetylsphingosine	10-21	insulin receptor substrate 1	Homo sapiens	108-113	
9710629-9	1998	These studies demonstrate ceramide"s capacity to inhibit activation of Akt and imply that this is a mechanism of antagonism of insulin-dependent physiological events, such as the peripheral activation of glucose transport and the suppression of apoptosis.	Ceramides	26-34	AKT serine/threonine kinase 1	Homo sapiens	71-74	
9710629-9	1998	These studies demonstrate ceramide"s capacity to inhibit activation of Akt and imply that this is a mechanism of antagonism of insulin-dependent physiological events, such as the peripheral activation of glucose transport and the suppression of apoptosis.	Ceramides	26-34	insulin	Homo sapiens	127-134	
9710629-9	1998	These studies demonstrate ceramide"s capacity to inhibit activation of Akt and imply that this is a mechanism of antagonism of insulin-dependent physiological events, such as the peripheral activation of glucose transport and the suppression of apoptosis.	Glucose	204-211	AKT serine/threonine kinase 1	Homo sapiens	71-74	
9710629-9	1998	These studies demonstrate ceramide"s capacity to inhibit activation of Akt and imply that this is a mechanism of antagonism of insulin-dependent physiological events, such as the peripheral activation of glucose transport and the suppression of apoptosis.	Glucose	204-211	insulin	Homo sapiens	127-134